scisparc.com (SPRC) Earnings growth forecast for next year

SciSparc (SPRC) - corporate logo

Demand for pharmaceuticals remains stable, although geopolitics and sanctions complicate raw material logistics. The development of unique cannabinoid treatments for the CNS provides SciSparc Ltd (SPRC) opportunities for market dominance. The target net income per share growth rate reflects the impact of these factors, with the metric holding at 0.00. The company is currently battling a liquidity shortage, cutting expenses due to costly clinical trials.

Clearmind Medicine (SPRC): Expected net earnings per share growth next year from 02/21/2024 to 11/15/2026

Analytical breakdowns for SciSparc Ltd

- share price and consensus valuation forecast:
Stock Price scisparc.com|SPRC - Consensus Target
- market capitalization details:
Market Capitalization Clearmind Medicine|SPRC - Value Adjusted for Debt and Cash
- book capitalization indicators:
Net Assets per Single Share SciSparc|SPRC - Total Stockholders' Equity|Market Value to Book Value Ratio scisparc.com|SPRC - Company Total Asset Base
- company total debt and liquidity indicators:
Total Debt to Capital SciSparc Ltd|SPRC - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital SciSparc Corp|SPRC - Company Total Debt Obligations|Debt to Book Capitalization Ratio SciSparc Corp|SPRC - Long-Term Debt Volume|Company Short-Term Debt SciSparc|Quick Ratio scisparc.com
- net income and valuation ratios data:
SPRC - Net Profit|Expected Profit SciSparc Ltd|SPRC - Company Value to Net Income|Forward P/E Multiple SciSparc Ltd.|SPRC - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Clearmind Medicine|SPRC - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months SciSparc|SPRC - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months scisparc.com|SPRC - Net earnings per one share growth for the current year|Earnings growth forecast for next year SciSparc Ltd
- total revenue and sales volume data:
SPRC - Company Sales Volume|Company Projected Revenue scisparc.com|SPRC - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio SciSparc Ltd.|SPRC - Trailing Twelve Months Sales Growth
Initial company analysis:SPRC, scisparc.com
Finished products of scisparc.com

The indicator calculates the expected percentage growth of net earnings per share based on consolidated analyst forecasts and current financial reporting data. This metric determines the fairness of the market valuation of SciSparc Ltd (SPRC), where inertial demand for CNS therapy drugs guarantees revenue stability, as reflected in the trend of the company's forward EPS estimates.

Competitor analysis

ALKS (alkermes.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Avadel Pharmaceuticals (AVDL)|Earnings growth forecast for next year ATAI|GHRS (GH Research plc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year mindmed.co MNMD|Compass Pathways (CMPS) - Expected net earnings per share growth next year|LBRX - Net earnings per share growth forecast for next year|DRUG: Net earnings per share growth forecast for next year|VNDA: Earnings growth forecast for next year|Expected net earnings per share growth next year Cybin Inc (CYBN)|Expected earnings per share growth for next year ANRO|Projected earnings per share growth rate for next year NRXP (NRx Pharmaceuticals)|Earnings growth forecast for next year CING|SILO - Expected net earnings per share growth next year|Earnings growth forecast for next year CPHI (China Pharma Holdings Inc.)|Expected earnings per share trend next year CMND|pacificbayminerals.com - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Seelos Therapeutics SEEL|VRPX (Virpax) - Expected earnings per share growth for next year|Karuna Therapeutics, Inc. - Expected earnings per share trend next year